Media Thread, page-1149

https://www.painchek.com/use-cases/babies-toddlers/
PainChek Infant App –  Initial Target Markets

1. Post vaccination

Approximately 140 million infants worldwide

- 95% fully immunised at 12 months after five immunization appointments1
- Covid -19 infant vaccination clinical studies ongoing with clear need to understand the occurrence of post vaccination pain

Australian Data
https://aifs.gov.au/facts-and-figures/births-in-australia


2. Post operative

Pain associated with surgical procedures (e.g. post tonsillectomy) & where parents are required to deliver pain management in the home


3. Partnerships & licensing

Collaboration with global therapeutic companies providing vaccination and pain medications for use by healthcare professional and families


https://www.painchek.com/latest-new...ed-growth-and-advances-in-new-global-markets/
Development of a direct-to-consumer program to commercialise PainChek Infant & children’s products

A direct-to-consumer market program has been initiated to build awareness of PainChek Infant & our children’s products, in preparation for the commercial market release later this year.

“A PainChek Infant direct-to-consumer market strategy is now in place to build parental demand for the technology – while continuing to generate supportive clinical evidence in readiness for a full commercial launch of PainChek Infant in 2023.” – Philip Daffas, CEO and Managing Director, PainChek

We are also continuing to collect clinical data to demonstrate the benefits of PainChek Infant. The Royal Children’s Hospital in Melbourne is working with parents and children to evaluate the use of PainChek Infant in the Emergency Department, and recruitment has begun in Europe for an infant circumcision project.